Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 27, 24 | -2.53 Decreased by -62.41% | -1.27 Decreased by -99.5% |
| Nov 7, 23 | -1.18 Increased by +4.84% | -1.58 Increased by +25.32% |
| Aug 8, 23 | -1.25 Increased by +5.3% | -1.65 Increased by +24.24% |
| May 5, 23 | -1.54 Decreased by -28.33% | -1.51 Decreased by -1.99% |
| Feb 23, 23 | -1.56 Decreased by -56% | -1.22 Decreased by -27.87% |
| Nov 8, 22 | -1.24 Decreased by -31.91% | -1.13 Decreased by -9.73% |
| Aug 4, 22 | -1.32 Decreased by -28.16% | -1.04 Decreased by -26.92% |
| May 5, 22 | -1.2 Decreased by -42.86% | -0.89 Decreased by -34.83% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 34.6 M Increased by +14.19% | -64 M Increased by +3.32% | Decreased by -184.97% Increased by +15.34% |
| Jun 30, 23 | 54.5 M Increased by +74.12% | -66.6 M Increased by +4.86% | Decreased by -122.2% Increased by +45.36% |
| Mar 31, 23 | 32.5 M Increased by +34.3% | -80.8 M Decreased by -27.44% | Decreased by -248.62% Increased by +5.1% |
| Dec 31, 22 | 38 M Increased by +44.49% | -79.9 M Decreased by -50.75% | Decreased by -210.26% Decreased by -4.34% |
| Sep 30, 22 | 30.3 M Increased by +226.34% | -66.2 M Decreased by -41.6% | Decreased by -218.48% Increased by +56.61% |
| Jun 30, 22 | 31.3 M Increased by +464.53% | -70 M Decreased by -39.2% | Decreased by -223.64% Increased by +75.34% |
| Mar 31, 22 | 24.2 M Increased by +336.87% | -63.4 M Decreased by -54.77% | Decreased by -261.98% Increased by +64.57% |
| Dec 31, 21 | 26.3 M Increased by +1.09 K% | -53 M Decreased by -27.57% | Decreased by -201.52% Increased by +89.24% |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.